Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
about
Dietary interventions to extend life span and health span based on calorie restrictionEverolimus-eluting stents in interventional cardiologyDetermining sensitivity to rapamycin and its analogues in breast cancer patientsSynergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor RapamycinTreating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.Burden of de novo malignancy in the liver transplant recipientInTERTesting association between telomerase, mTOR and phytochemicalsNovel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activationVitamin E succinate induces apoptosis via the PI3K/AKT signaling pathways in EC109 esophageal cancer cellsApoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.Targeting MYC Dependence by Metabolic Inhibitors in CancerRapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.Rapamycin enhances the antiproliferative effect of transforming growth factor-β on MCF-7 human breast cancer cellsAntiangiogenic therapy using sunitinib combined with rapamycin retards tumor growth but promotes metastasis.Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells.Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells.Experimental approaches for the treatment of malignant gliomas.Ligands for FKBP12 increase Ca2+ influx and protein synthesis to improve skeletal muscle function.Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives.Rapamycin promotes beta-amyloid production via ADAM-10 inhibition.α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways.Calcineurin inhibitors and rapamycin: cancer protection or promotion?Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysisEfficacy and comparative effectiveness of sirolimus as an anticancer drug.Astaxanthin improves stem cell potency via an increase in the proliferation of neural progenitor cellsCancer metabolism: strategic diversion from targeting cancer drivers to targeting cancer suppliersS6K1 and mTOR regulate Rac1-driven platelet activation and aggregation.Regulation of germline stem cell proliferation downstream of nutrient sensing.Structural studies and anticancer activity of a novel class of β-peptides.Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine.The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALLRapamycin ameliorates experimental autoimmune uveoretinitis by inhibiting Th1/Th2/Th17 cells and upregulating CD4+CD25+ Foxp3 regulatory T cells.Treatment of recurrent or metastatic renal cell carcinoma.Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition.Insulin-like growth factor binding protein-3 mediates interleukin-24-induced apoptosis through inhibition of the mTOR pathway in prostate cancer.Inhibitors of the mammalian target of rapamycin.Analysis of whole genomic expression profiles and screening of the key signaling pathways associated with pancreatic cancer
P2860
Q24595003-00085012-6132-402E-8CE6-EB24AF0BE07BQ24630321-F6952FE5-2B81-495E-92DD-2A6D5727D1FAQ24797136-8DEC1332-8BF7-4F77-BE49-ECA905B8A292Q24811525-C5441112-C602-44EC-A7C5-889E5B951254Q24813788-79945E24-FECE-4830-850C-B2F92D42E68BQ26859216-0AC1B12D-E085-4C42-999A-364E54979CB7Q28262993-F973E482-9B7F-484A-B5E4-7DE052A2F26BQ28572582-4B1CEBC0-DCD2-4E3E-8DA0-572F0FF23346Q28830715-700E62FE-CE2E-486B-8716-ABAD4783D915Q30439284-E3409DA0-B4F1-449F-883A-1AD3F23C60C7Q33274011-65E5B420-E93E-4A81-AB56-D10B94E95CA2Q33414529-3A88FFF7-4399-4EA7-AFEE-0B2F1DF001D3Q33423777-DF7B779C-0BEB-4983-9549-D6E0EE95ECC6Q33608493-64D15BEB-F305-457C-B92D-FFBB7FA24F77Q33638550-887E2F44-4E3A-4B1B-83C7-CED0160BEEFBQ33847432-B219E3C9-711D-435B-B7B7-2DDF744FBEB8Q33912305-A9B96F38-CDB1-4BBF-97C5-5C257487B209Q33990018-BF7A6A5D-AF32-47AC-8249-DA7363CD5450Q34005315-61931154-FAD1-47A9-9BAE-B4EFC9A523F7Q34127138-CBA34472-0B33-42F0-BDFF-2613D9DCCEB8Q34170669-393FD5A3-9159-4973-B5FA-A8C2D0CDF0D3Q34351372-8853DC5A-9870-47AB-93DE-C8F2BDEB67DEQ34576437-958C7AF0-20C1-463F-BA1D-D6C5C2E48A4DQ34577504-168A6163-70CF-4D1A-BD60-11D33BBAFB5EQ34578721-D2FBE12B-DCF3-416B-A3D4-1E36C80F6133Q34778631-59596B7C-7C3D-4BBA-9E78-A093F8AFD6B6Q34891527-D17CEEDA-F1FF-4847-B90C-1110F54DF254Q35002181-8B4DFAA3-CCDB-4254-AE73-8E03EABF6039Q35161318-142FD64C-0625-4881-89F7-A62BE293DEB5Q35220422-6091801F-415F-43C4-8B6B-70D38EEC177FQ35250708-14A2EBAD-F311-44FD-B229-A7894966D7DAQ35435384-E183C6D6-83BE-4C38-BB4F-B44F491F8C55Q35822579-9F8977AD-E69F-4AAE-86C3-E91E383486F3Q35850028-D44EA856-99A2-494A-B593-66CC4A9D173EQ35964539-47DBA257-5AE2-4D0C-8A82-433738CEA6E9Q35987766-CBE1B578-CDA9-4537-AA23-9F8729AD5CB3Q36071993-24935FB7-B942-462F-BD1E-C853B053F50CQ36094078-1C3449B7-C64F-4479-A264-3652AAE8803CQ36099427-2FFB1B06-F4EA-4C42-A79C-D2E8C44C4B6AQ36196775-54F92AC5-83CA-4FC7-BB93-114BB0D755D0
P2860
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
@ast
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
@en
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
@nl
type
label
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
@ast
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
@en
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
@nl
prefLabel
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
@ast
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
@en
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
@nl
P2860
P921
P3181
P356
P1476
Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
@en
P2093
P2860
P2888
P304
P3181
P356
10.1038/SJ.BJC.6602162
P407
P577
2004-10-18T00:00:00Z
P5875
P6179
1048127229